Immunome (NASDAQ:IMNM) Hits New 12-Month High – What’s Next?

Immunome, Inc. (NASDAQ:IMNM) hit a new 52-week high on Wednesday . The company traded as high as $17.94 and last traded at $17.76, with a volume of 262793 shares. The stock had previously closed at $17.52.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IMNM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Evercore ISI assumed coverage on Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday. Finally, The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Immunome Price Performance

The firm’s 50 day moving average price is $13.13 and its two-hundred day moving average price is $10.63. The stock has a market cap of $1.60 billion, a PE ratio of -5.89 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently bought and sold shares of the company. MetLife Investment Management LLC grew its position in shares of Immunome by 19.1% during the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after purchasing an additional 6,792 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Immunome by 55.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after acquiring an additional 275,000 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of Immunome during the first quarter worth about $1,776,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Immunome by 34.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock worth $4,135,000 after purchasing an additional 157,135 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Immunome in the second quarter worth approximately $793,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.